{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:13:40Z","timestamp":1772817220102,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> Previous studies have demonstrated the efficacy of apatinib and anlotinib for the treatment of sarcomas. However, more clinical data and evidence are needed to support clinical treatment selection and study design. Here, we evaluated the effectiveness and safety of these two drugs for the treatment of sarcomas. <jats:italic>Methods<\/jats:italic> We retrospectively reviewed the data of 110 patients with advanced osteosarcoma (<jats:italic>n<\/jats:italic>\u2009=\u200932) or soft tissue sarcoma (STS, <jats:italic>n<\/jats:italic>\u2009=\u200978) who received oral apatinib or anlotinib therapy during May 2016\u2013February 2019 at two centers. Patients were divided into the apatinib and anlotinib groups. <jats:italic>Results<\/jats:italic> Among osteosarcoma patients, the objective response rates (ORRs) for the apatinib and anlotinib groups were 15.79% (3\/19) and 7.69% (1\/13), respectively. The disease control rates (DCRs) were 63.16% (12\/19) and 30.77% (4\/13), and the median progression-free survival (m-PFS) was 4.67\u2009\u00b1\u20093.01 and 2.67\u2009\u00b1\u20091.60\u00a0months, respectively. Among STS patients, ORRs for the apatinib and anlotinib groups were 12.24% (6\/49) and 13.79% (4\/29), respectively. The DCRs were 59.18% (29\/49) and 55.17% (16\/29), and m-PFS was 7.82\u2009\u00b1\u20096.90 and 6.03\u2009\u00b1\u20094.50\u00a0months, respectively. Regarding adverse events (AEs), apatinib was associated with a higher incidence of hair hypopigmentation and pneumothorax, while anlotinib was associated with a higher incidence of pharyngalgia or hoarseness. <jats:italic>Conclusion<\/jats:italic> Both apatinib and anlotinib were effective for the treatment of sarcomas. However, the effectiveness of the two drugs and associated AEs varied based on the histological type of sarcoma. These differences may be due to their different sensitivities to targets such as RET, warranting further study.<\/jats:p>","DOI":"10.1007\/s10637-020-00912-7","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T14:02:48Z","timestamp":1582639368000},"page":"1559-1569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Zhichao","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhui","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinpo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4978-1501","authenticated-orcid":false,"given":"Jiaqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"912_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00270-019-02259-w","volume":"42","author":"K Bourcier","year":"2019","unstructured":"Bourcier K, Le Cesne A, Tselikas L et al (2019) Basic knowledge in soft tissue sarcoma. Cardiovasc Intervent Radiol 42:1255\u20131261","journal-title":"Cardiovasc Intervent Radiol"},{"key":"912_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.6004\/jnccn.2017.0017","volume":"15","author":"JS Biermann","year":"2017","unstructured":"Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, Didwania A, Fabbri N, Hornicek FJ, Kuechle JB, Lindskog D, Mayerson J, McGarry S, Million L, Morris CD, Movva S, O'Donnell RJ, Randall RL, Rose P, Santana VM, Satcher RL, Schwartz H, Siegel HJ, Thornton K, Villalobos V, Bergman MA, Scavone JL (2017) NCCN guidelines insights: bone Cancer, version 2.2017. J Natl Compr Cancer Netw 15:155\u2013167","journal-title":"J Natl Compr Cancer Netw"},{"key":"912_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.6004\/jnccn.2018.0025","volume":"16","author":"M Von Mehren","year":"2018","unstructured":"Von Mehren M, Randall RL, Benjamin RS et al (2018) Soft Tissue Sarcoma, Version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16:536\u2013563","journal-title":"J Natl Compr Cancer Netw"},{"key":"912_CR4","first-page":"310","volume":"38","author":"Oncology SCoCA-CACSoC","year":"2016","unstructured":"Oncology SCoCA-CACSoC (2016) Chinese expert consensus on diagnosis and treatment of soft tissue sarcomas (version 2015). Zhonghua Zhong Liu Za Zhi 38:310\u2013320","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"912_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.soc.2016.05.001","volume":"25","author":"VY Jo","year":"2016","unstructured":"Jo VY, Doyle LA (2016) Refinements in sarcoma classification in the current 2013 World Health Organization classification of Tumours of soft tissue and bone. Surg Oncol Clin N Am 25:621\u2013643","journal-title":"Surg Oncol Clin N Am"},{"key":"912_CR6","first-page":"410","volume":"43","author":"EK Singhi","year":"2018","unstructured":"Singhi EK, Moore DC, Muslimani A (2018) Metastatic soft tissue sarcomas: a review of treatment and new pharmacotherapies. P T 43:410\u2013429","journal-title":"P T"},{"key":"912_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/annonc\/mdq276","volume":"21","author":"J Ritter","year":"2010","unstructured":"Ritter J, Bielack SS (2010) Osteosarcoma. Ann Oncol 21:320\u2013325","journal-title":"Ann Oncol"},{"key":"912_CR8","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1200\/JCO.2011.38.4420","volume":"30","author":"S Ferrari","year":"2012","unstructured":"Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F, Comandone A, Bertulli R, Bisogno G, Palmerini E, Alberghini M, Parafioriti A, Linari A, Picci P, Bacci G (2012) Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG\/OS-1. J Clin Oncol 30:2112\u20132118","journal-title":"J Clin Oncol"},{"key":"912_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, Hartmann JT, Sch\u00f6ffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Liti\u00e8re S, Hermans C, Fisher C, Hogendoorn PC, dei Tos A, van der Graaf W, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2014) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15:415\u2013423","journal-title":"Lancet Oncol"},{"key":"912_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jjco\/hyy053","volume":"48","author":"S Miyamoto","year":"2018","unstructured":"Miyamoto S, Kakutani S, Sato Y, Hanashi A, Kinoshita Y, Ishikawa A (2018) Drug review: Pazopanib. Jpn J Clin Oncol 48:503\u2013513","journal-title":"Jpn J Clin Oncol"},{"key":"912_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3892\/or.2017.5735","volume":"38","author":"L Xie","year":"2017","unstructured":"Xie L, Ji T, Guo W (2017) Anti-angiogenesis target therapy for advanced osteosarcoma. Oncol Rep 38:625\u2013636","journal-title":"Oncol Rep"},{"key":"912_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","volume":"20","author":"F Duffaud","year":"2018","unstructured":"Duffaud F, Mir O, Boudou-Rouquette P et al (2018) Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20:120\u2013133","journal-title":"Lancet Oncol"},{"key":"912_CR13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","volume":"102","author":"S Tian","year":"2011","unstructured":"Tian S, Quan H, Xie C et al (2011) YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 102:1374\u20131380","journal-title":"Cancer Sci"},{"key":"912_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-018-0903-9","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ (2018) Apatinib: a review in advanced gastric Cancer and other advanced cancers. Drugs 78:747\u2013758","journal-title":"Drugs"},{"key":"912_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D et al (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11:120","journal-title":"J Hematol Oncol"},{"key":"912_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40880-019-0383-7","volume":"39","author":"M Zhou","year":"2019","unstructured":"Zhou M, Chen X, Zhang H et al (2019) China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun 39:36","journal-title":"Cancer Commun"},{"key":"912_CR17","doi-asserted-by":"publisher","first-page":"e15650","DOI":"10.1097\/MD.0000000000015650","volume":"98","author":"Z Tian","year":"2019","unstructured":"Tian Z, Gu Z, Wang X et al (2019) Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy. Medicine 98:e15650","journal-title":"Medicine"},{"key":"912_CR18","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.2147\/CMAR.S207150","volume":"11","author":"Z Tian","year":"2019","unstructured":"Tian Z, Wang X, Liu Z, Wang J, Yao W, Zhao Y, Gao S, Zhang P, Ge H (2019) Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions. Cancer Manag Res 11:5293\u20135300","journal-title":"Cancer Manag Res"},{"key":"912_CR19","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","volume":"24","author":"Y Chi","year":"2018","unstructured":"Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G, du F, Sun Y, Wu Q, Qu G, Wang S, Song J, Yu J, Lu Y, Zhu X, Niu X, He Z, Wang J, Yu H, Cai J (2018) Safety and efficacy of Anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res 24:5233\u20135238","journal-title":"Clin Cancer Res"},{"key":"912_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/14737140.2019.1686979","volume":"19","author":"CP Wilding","year":"2019","unstructured":"Wilding CP, Elms ML, Judson I, Tan AC, Jones RL, Huang PH (2019) The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Rev Anticancer Ther 19:971\u2013991","journal-title":"Expert Rev Anticancer Ther"},{"key":"912_CR21","first-page":"378","volume":"3","author":"Z Rongyuan","year":"2019","unstructured":"Rongyuan Z, Zhiming W, Xi G et al (2019) The short-term efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma. Chin J Clin Med 3:378\u2013381","journal-title":"Chin J Clin Med"},{"key":"912_CR22","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1634\/theoncologist.2018-0542","volume":"24","author":"L Xie","year":"2019","unstructured":"Xie L, Xu J, Sun X, Tang X, Yan T, Yang R, Guo W (2019) Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist 24:e542\u2013e550","journal-title":"Oncologist"},{"key":"912_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/CAD.0000000000000778","volume":"30","author":"Y Weitao","year":"2019","unstructured":"Weitao Y, Fangxing W, Qiqing C et al (2019) Efficacy and safety of apatinib in advanced sarcoma. Anti-Cancer Drugs 30:749\u2013756","journal-title":"Anti-Cancer Drugs"},{"key":"912_CR24","first-page":"309","volume":"41","author":"SL Li","year":"2019","unstructured":"Li SL, Yang QK, Chen P, Zheng K, Wang W, Pei Y, Zhang XJ (2019) Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis. Zhonghua Zhong Liu Za Zhi 41:309\u2013314","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"912_CR25","doi-asserted-by":"publisher","first-page":"e11734","DOI":"10.1097\/MD.0000000000011734","volume":"97","author":"K Zheng","year":"2018","unstructured":"Zheng K, Xu M, Wang L et al (2018) Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: a single-center observational study. Medicine 97:e11734","journal-title":"Medicine"},{"key":"912_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdr151","volume":"23","author":"G Grignani","year":"2012","unstructured":"Grignani G, Palmerini E, Dileo P et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian sarcoma group study. Ann Oncol 23:508\u2013516","journal-title":"Ann Oncol"},{"key":"912_CR27","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/aps.2012.76","volume":"33","author":"W-f Mao","year":"2012","unstructured":"Mao W-f, M-h S, Gao P-t et al (2012) The important roles of RET, VEGFR2 and the RAF\/MEK\/ERK pathway in cancer treatment with sorafenib. Acta Pharmacol Sin 33:1311\u20131318","journal-title":"Acta Pharmacol Sin"},{"key":"912_CR28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H et al (2018) Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109:1207\u20131219","journal-title":"Cancer Sci"},{"key":"912_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Sch\u00fctz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245\u2013255","journal-title":"Int J Cancer"},{"key":"912_CR30","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109","journal-title":"Cancer Res"},{"key":"912_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s12276-019-0221-7","volume":"51","author":"Z Liao","year":"2019","unstructured":"Liao Z, Li F, Zhang C et al (2019) Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med 51:24","journal-title":"Exp Mol Med"},{"key":"912_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12885-018-4303-z","volume":"18","author":"L Xie","year":"2018","unstructured":"Xie L, Guo W, Wang Y et al (2018) Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China. BMC Cancer 18:396","journal-title":"BMC Cancer"},{"key":"912_CR33","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","volume":"31","author":"J Li","year":"2013","unstructured":"Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H (2013) Apatinib for chemotherapy-refractory advanced metastatic gastric Cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 31:3219\u20133225","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00912-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00912-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00912-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:45:45Z","timestamp":1678509945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00912-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00912-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"4 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors who took part in this study indicate that they do not have anything to declare regarding funding or conflicts of interest with respect to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Formal consent was not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are included in this published article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}